Anuh Pharma's FY26 revenue rose 16.6% but profit fell 13.3%

Anuh Pharma reported a 16.6% rise in annual revenue to an undisclosed amount, but profit after tax dropped 13.3% for the year ended March 2026. That is the headline number that jumps out from an otherwise standard audited results filing. The board also recommended a dividend of ₹1.50 per share, a modest increase from prior levels, and approved routine items such as director reappointments and the appointment of an internal auditor and cost auditor. The divergence between revenue and profit is the real story here. It suggests the company is growing but not efficiently, either because input costs are rising or pricing power is weakening. For investors, the dividend offers some return but does not address the underlying margin question. The next quarterly numbers will be the first test of whether this is a one-off or a trend.